Phase 1 Epilepsy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 18 and 55 years of age (inclusive)
- People with a body mass index (a measure of body weight relative to height) between 18 and 32
- People who are generally in good health, with no significant medical concerns found during health checks, blood tests, urine tests, heart tracing (ECG), or physical examination at the screening stage, as assessed by the study doctor
- Both male and female participants who agree to use adequate contraception and agree not to donate sperm or eggs during the time periods set out in the study protocol
Who may not be able to join:
- People who test positive for HIV, Hepatitis B (HBV), or Hepatitis C (HCV)
- People with a history of cancer, except for certain skin cancers (basal cell carcinoma or squamous cell carcinoma) or early-stage cervical cell changes (carcinoma in situ) that have already been treated
- People with a history of alcohol dependency or recreational drug use within the past 2 years, or those who test positive for alcohol or tobacco at the screening or first check-in visit
- Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Actio Bioscences, Inc.
Phone: +1 (858) 679-5891
Australian sites
(+61) 2 9382 5800
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety and tolerability (incidence, severity, and dose-relationship of adverse events); Safety and tolerability (incidence, severity, and dose-relationship of clinically significant changes in laboratory parameters)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.